D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDE
D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDE Basic information
- Product Name:
- D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDE
- Synonyms:
-
- [D-ARG1,D-TRP7,9,LEU11]-SUBSTANCE P HYDROCHLORIDE
- (D-ARG1,D-TRP7,9,LEU11)-SUBSTANCE P
- D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2
- D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDE
- H-D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2
- (D-arg1,D-trp7,9,leu11)-substance P*acetate
- D-ARG1,D-TRP7,9,LEU11]-SUBSTANCE P (SPANTIDE)
- M.W. 1497.80 C75H108N20O13
- CAS:
- 91224-37-2
- MF:
- C75H108N20O13
- MW:
- 1497.79
- Product Categories:
-
- Tachykinin receptor
- Mol File:
- 91224-37-2.mol
D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDE Chemical Properties
- Density
- 1.43±0.1 g/cm3(Predicted)
- storage temp.
- −20°C
- pka
- 13.31±0.20(Predicted)
- form
- Powder
- color
- White to off-white
- Water Solubility
- Soluble to 1 mg/ml in water
MSDS
- Language:English Provider:SigmaAldrich
D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDE Usage And Synthesis
Uses
Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation[1][2][3].
in vivo
Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals[2].
Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β[3].
| Animal Model: | Female, 8-week-old C57BL/6 (B6) and BALB/c mice[3]. |
| Dosage: | 36 μg/mouse. |
| Administration: | IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection). |
| Result: | At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice. Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi. Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi. Significantly reduced the level of IL-18 mRNA at 1 day pi. |
IC 50
NK1: 230 nM (Ki); NK2: 8150 nM (Ki)
References
[1] J C Beaujouan, et al. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol. 1993 Mar;108(3):793-800. DOI:10.1111/j.1476-5381.1993.tb12880.x
[2] M Zubrzycka, et al. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. Endocr Regul. 2000 Mar;34(1):13-8. PMID:10808247
[3] Linda D Hazlett, et al. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):797-807. DOI:10.1167/iovs.06-0882
D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDESupplier
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- 21-61263452 13641803416
- ymbetter@glbiochem.com
- Tel
- 025-83697070
- info@chemlin.com.cn
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-50135380
- shchemsky@sina.com